Favipiravir(259793-96-9)
July 3, 2020
6-bromo-3-hydroxypyrazine-2-carboxamide
July 3, 2020
3,6-dichloropyrazine-2-carbonitrile
3,6-dichloropyrazine-2-carbonitrile is used to produce Favipiravir, a drug used to treat advanced Ebola virus infection in small animal models.
Favipiravir, also known as T-705 or Avigan, is an antiviral drug being developed by Toyama Chemical (Fujifilm group) of Japan with activity against many RNA viruses. In February 2020 Favipiravir was being studied in China for experimental treatment of the emergent COVID-19 (novel coronavirus) disease and it has show positive results.
3,6-dichloropyrazine-2-carbonitrile(356783-16-9) Information
| Product | 3,6-dichloropyrazine-2-carbonitrile | ||
| CAS No. | 356783-16-9 | ||
| Synonyms | Favipiravir intermediate;
6-Dichloropyrazine-2-carbonitrile; 2-Pyrazinecarbonitrile; 3,6-Dichloro-2-pyrazinecarbonitrile; |
||
| Availability | In Stock | ||
| MF. | C5HCl2N3 | MW. | 173.98754 |
| Appearance | Yellowish to off – white crystalline powder | Purity | 98% |
| Application |
For research use only |
Storage | RT |
| COA & NMR | Download | MSDS | Download |
[Reference]
[1] Koons C (7 August 2014). “Ebola Drug From Japan May Emerge Among Key Candidates”. Bloomberg.com.
[2] “AIFA precisa, uso favipiravir per COVID-19 non autorizzato in Europa e USA, scarse evidenze scientifiche sull’efficacia”. aifa.gov.it (in Italian). Retrieved 2020-03-23.
[3] Favipiravir to Treat COVID-19: Q&A with Boris Juelg, MD, PhD”. Mass General Advances in Motion. Retrieved 29 April 2020.
[4] Favipiravir
